News/ News/ R&D Sarepta DMD rival PepGen files $115m IPO Phil Taylor Duchenne muscular dystrophy, financing, NS Pharma, Oligonucleotide, PepGen, Sarepta 0 Comment Just days after dosing its first patient in a Duchenne muscular dystrophy trial, US biotech PepGen has pushed Share X Sarepta DMD rival PepGen files $115m IPO https://pharmaphorum.com/news/sarepta-dmd-rival-pepgen-files-115m-ipo/
Duchenne muscular dystrophy, financing, NS Pharma, Oligonucleotide, PepGen, Sarepta
0 Comment
